A Study of LP-168 in Healthy Volunteers

Clinical trial NCT05432713 · COMPLETED

Trial details

NCT number: NCT05432713
Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Sclerosis NMO Spectrum Disorder

Start date: 2022-05-14
Primary completion: 2022-11-20
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.